Non-operative management of patients with abdominal aortic aneurysm (aaa) is required for several different reasons. since these patients have an increased risk of cardiovascular death therapy to reduce cardiovascular events is essential. tr eatment is in line with the medical management of coronary artery disease including smoking cessation, statins and anti-platelet therapy.some of these therapies also will slow aneurysm growth, which is atarget in the management of patients with small aaa.asyet there is no targeted therapy that reduces aneurysm growth, but there is active research in this area. medical management also is required to reduce peri-operative risks, stabilise endovascular aneurysm repair and minimise the risk of rupture in those with large aaa unfit for aneurysm repair.
diovascular events (6, 7). Women with AAA may be at particularly high risk, their death rate being twice that of the age-sex matched population, even after successful AAA repair (8). The medical management of patients with AAA needs to be tailored to address these aspects, in addition to monitoring AAA progression in order to decide about open or endoluminalr epair, but evidencef romr andomised trialsi s limited.
STRATEGIES foR CARDIoVASCULAR RISK REDUCTIon
Thereh ave been no randomised trials of cardiovascular risk reduction in patients with AAA, so that current recommendations mostly derive from risk reduction trials inpatients with other cardiovascular disease and observationals tudies (often retrospective) of patients with AAA. The most important modifiable risk factor for AAA in those with screen-detected AAA is cigarette smoking (9). Population studies indicate that smoking is associated with arelative risk of 5for the presence of AAA. Smoking is associated with am arked increased risk of morbidity and mortality from al arge range of other conditions, including ischaemic heart disease, stroke, lung cancer InTRoDUCTIon Randomised trials have suggested that screening for abdominal aortic aneurysm (AAA) in at risk populations can reduce related mortality (1, 2). The principal group likely to benefit arem iddle-aged and elderly male smokers (3). The introduction of ultrasound screening will add to the number of AAA already identified by incidental imaging, in particular those of small diameter (4, 5). In the Aneurysm Detection And Management study (ADAM) and aD utch primary cares creening programme >90% of the small AAAs identified measured am aximum diameter of <55mm (4, 5). The management of these small AAAs is usually conservative. However,t he identification of an AAA also has implications for mortality and morbidity secondary to associated atherosclerosis (6, 7). Patients with AAA areatincreased risk of car-and emphysema (10) . nicotine replacement therapy and counselling have been demonstrated to improve the rate of smoking cessation significantly and newer treatments includingb uproprion and varencline should be added to nicotine replacement therapy to enhance cessation rates (11) .
Dyslipidaemia and hypertension areless powerful risk factors for AAA. The control of lipids and blood pressureinpatients with AAA is important in reducing mortality in this group. The use of statins has been associated with an improved survival after AAA repair,w ith am oret han 3-fold reduction in risk of cardiovascular death associated with statin usage, HR 0.3 [95%CI 0.2-0.6] p<0.001 in ar etrospective single centreseries and asimilar risk reduction in the EURoSTAR registry (12, 13) . However,f or patients randomised in the EVAR 1trial, statin usage was not associated with improved 5-year survival (14) . Since patients with AAA have an increased risk of cardiovascular events and death, the results of the Heart Protection study would suggest that all AAA patients should receive statin therapy,i rrespective of serum cholesterol concentration (15) . The preferred first line drug for the treatment of hypertension in most of these older patients is an angiotensin converting enzyme (ACE) inhibitor,a lthough these drugs should be used with caution in those with renal artery stenosis (16) . of greater worry is the problem that anumber of studies indicate that management of lipids and blood pressurei so ften sub-optimal in patients with AAA by comparison to those presenting with coronary artery symptoms (17) . Lloyd GM et al. have shown that patients visiting av ascular surgery outpatient clinic beforeo ra fter AAA repair have been sub-optimally treated with regardt oc urrent guidelines (18) . Specifically,o nly 41% with an indication for statin treatment have actually received this therapy,a nd many others have not had ar ecent plasma lipid measurement. Similar results have been demonstrated for other pharmacological interventions including anti-platelet agents, ACE inhibitors and beta blockers. Thereisincreasing awareness that the intraluminal thrombus may have ar ole in AAA progression (19) , but the likely benefit of anti-platelet therapy on AAA progression has not been investigated prospectively.
PERIoPERATIVE MEDICAL THERAPy foR THoSE UnDERGoInG AAA REPAIR Medical therapy to reduce cardiovascular risk is particularly critical around the time of operative intervention to repair AAA when the mortality for endoluminal and open surgery is approximately 2and 5%, respectively (20) . The main cause of mortality are perioperative cardiac events. In most centres patients ares tratified based on cardiac history with those at high risk for cardiac events undergoing further imaging. β -blockers have been shown to improve perioperative cardiac morbidity and mortality by 10-fold following major vascular surgery in the 10% of patients at highest cardiac risk (21) . However,s imilar benefit was not observed in those at lower risk, or in the large PoISE trial (22, 23) . Another small randomised trial in vascular surgical patients indicated that statin therapy reduced the combined endpoint of cardiac events and mortality and this view is supported by larger non-randomised cohort studies of patients undergoing AAA repair; these and other studies of peri-operative statin use have been included in arecent systematic review (24) . In patients taking statins, the incidence of myocardial infarction or stroke within 30 days of surgery was only 3.7% compared with 11%i nt hose not taking statins, adjusted hazardr atio 0.24 (95% CI 0.11-0.54). Larger randomised trials arer equired to definitely show a benefit of perioperative statin use (24) .
RISK of AAA RUPTURE AnD TREATMEnT of AAA RUPTURE
Thereare two studies that suggest concurrent medications that might reduce the risk of ruptureinthose with large aneurysms unfit for intervention. Analysis of alarge Canadian data-base has suggested that concurrent use of ACE inhibitors is associated with a reduced risk of aortic rupture ( 25) . Analysis of the rupturer ate of large aneurysms in the EVAR 2t rial has shown, in a post-hoc analysis, that patients taking statins at baseline have half the risk of aneurysm rupturecompared to those not taking statins at baseline (26) .
It might be considered that medical management has no place in this condition. However,preoperative resuscitation guidelines should address the issue of hypotensive haemostasis (27, 28) . Therei se vidence from haemorrhagic trauma that mortality is reduced if preoperative fluid resuscitation is limited to maintaining blood pressurea tb elow normal levels. With ap ractice of hypotensive haemostasis, some have demonstrated excellent results for endovascular repair of ruptured AAA, with 30-day operative mortality reported to be as low as 11% ( 29) . Although, the selectionofgood prognosis patients for this approach may partially explain the favourable outcomes.
STRATEGIES To REDUCE AAA GRoWTH
It is likely that therapies aimed at reducing cardiovascular events in patients with AAA will also slow aneurysm growth. Smoking has been associated with AAA progression in anumber of studies (30) . Statins have been associated with slower AAA growth in two small retrospective studies (31, 32) . Associations between hypertension and dyslipidaemia with AAA growth have been difficult to assess due to varying definitions of these conditions, concurrent treatment and study power (33) . The only large randomised controlled trial investigating drug therapy for AAA assessed the β -blocker propranol (34) . Due to side effects 42% of patients discontinued treatment and by intention to treat analysis therapy did not reduce AAA growth rate and significantly impaired quality of life (34) . Therea re several smaller underpowered randomised trials of antibiotics, with AAA growth rate as the primary outcome measure, that provide inconclusive results. The national Institute of Health has providedstart-up funding to assess the feasibility of arandomised trial of doxycycline in the USA (Baxter BT,personal communication).
IMPRoVInG THE DURABILITy of EnDoVASCULAR REPAIR
Themain cause of failurefollowing endovascular repair of AAA is failuret oa dequately exclude the weakened aortic wall from the circulation associated with continued aortic expansion. Approximately 20% of patients requirer e-intervention for this problem within 4years of surgery (35) . At present thereare no recognised drug therapies which have been demonstrated to improve durability of EVAR. Since the main causes of failuretocompletely exclude the aneurysm areanatomical unsuitability for EVAR and graft failurei tm ight be considered that medical therapy has asmall part to play in improving outcome. However, strategies that inhibit aortic destruction may be particularly helpful in this group in which partial offloading of the pressureonthe aortic wall already has occurred. However,asmall randomised trial of doxycycline did not show that this therapy was associated with areduction in endoleaks (36).
fUTURE DIRECTIonS: LoCAL VERSUS SySTEMIC THERAPy AnD BIoMARKER DIRECTED THERAPy
Since AAA often is af ocal condition it would be attractive to have alocally applicable medical therapy rather than systemic treatment which may have effects on many other organs. The combination of a locally applied therapy with other interventions such as endoluminal grafting or stenting would be apossible means of reducing the requirement for re-intervention. These issues are beginning to be investigated in experimental models of AAA. Since natural history studies of small AAAs have emphasised that growth is variable both between and within patients over time (30) , therei san eed to develop biomarkers to identify patients requiring targeted therapy to minimise AAA growth. Alarge number of serum tests and genetic markers arep resently being investigated as biomarkers to predict AAA behaviour,h owever,a t present these markers have generally not been found to havesufficient accuracy in modelling AAA behaviour (33) . The application of proteomic and genomic techniques to large multicentrec ohorts of AAA patients is expected to advance the development of such biomarkers. 
